Fotios Asimakopoulos

Title(s)	Associate Professor In Residence, Medicine
School	Health Sciences
vCard	Download vCard

Biography

Education and Training

University of Cambridge, Cambridge UK	MD PhD	01/1997	Medicine, Hematology
Hebrew University of Jerusalem, Jerusalem Israel	Golda Meir Fellow	06/1999	Hematology
BWH, Harvard Medical School, Boston MA	Residency	06/2001	Internal Medicine
Memorial Sloan-Kettering Cancer Center, New York, NY	Fellowship	06/2009	Medical Oncology

Overview

Interests

Multiple Myeloma, Immunotherapy, Cancer vaccines, Stem cell transplant, Cellular therapy

ORNG Applications

Featured Publications

Bibliographic

Publications

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.

List All | Timeline

Dhakal B, Pagenkopf A, Mushtaq MU, Cunningham AM, Flietner E, Morrow Z, Papadas A, Hope C, Leith C, Hematti P, Hari P, Callander NS, Asimakopoulos F. Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma. Leuk Lymphoma. 2019 Oct; 60(10):2558-2562. PMID: 30845856.

View in: PubMed
Asimakopoulos F. TIGIT checkpoint inhibition for myeloma. Blood. 2018 10 18; 132(16):1629-1630. PMID: 30337318.

View in: PubMed
Mushtaq MU, Papadas A, Pagenkopf A, Flietner E, Morrow Z, Chaudhary SG, Asimakopoulos F. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. J Immunother Cancer. 2018 07 03; 6(1):65. PMID: 29970158.

View in: PubMed
Dhakal B, Szabo A, Chhabra S, Hamadani M, D'Souza A, Usmani SZ, Sieracki R, Gyawali B, Jackson JL, Asimakopoulos F, Hari PN. Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Mar 01; 4(3):343-350. PMID: 29302684.

View in: PubMed
Papadas A, Asimakopoulos F. Mechanisms of Resistance in Multiple Myeloma. Handb Exp Pharmacol. 2018; 249:251-288. PMID: 28315070.

View in: PubMed
Huynh M, Pak C, Markovina S, Callander NS, Chng KS, Wuerzberger-Davis SM, Bakshi DD, Kink JA, Hematti P, Hope C, Asimakopoulos F, Rui L, Miyamoto S. Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-?B activity and increases drug resistance in multiple myeloma. J Biol Chem. 2018 02 16; 293(7):2452-2465. PMID: 29279332.

View in: PubMed
Asimakopoulos F, Hope C, Johnson MG, Pagenkopf A, Gromek K, Nagel B. Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche. J Leukoc Biol. 2017 08; 102(2):265-275. PMID: 28254840.

View in: PubMed
Hope C, Foulcer S, Jagodinsky J, Chen SX, Jensen JL, Patel S, Leith C, Maroulakou I, Callander N, Miyamoto S, Hematti P, Apte SS, Asimakopoulos F. Immunoregulatory roles of versican proteolysis in the myeloma microenvironment. Blood. 2016 08 04; 128(5):680-5. PMID: 27259980.

View in: PubMed
Jensen JL, Hope C, Asimakopoulos F. Deploying myeloid cells against myeloma. Oncoimmunology. 2016 Mar; 5(3):e1090076. PMID: 27141348.

View in: PubMed
Gupta A, Place M, Goldstein S, Sarkar D, Zhou S, Potamousis K, Kim J, Flanagan C, Li Y, Newton MA, Callander NS, Hematti P, Bresnick EH, Ma J, Asimakopoulos F, Schwartz DC. Single-molecule analysis reveals widespread structural variation in multiple myeloma. Proc Natl Acad Sci U S A. 2015 Jun 23; 112(25):7689-94. PMID: 26056298.

View in: PubMed
Pak C, Callander NS, Young EW, Titz B, Kim K, Saha S, Chng K, Asimakopoulos F, Beebe DJ, Miyamoto S. MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells. Integr Biol (Camb). 2015 Jun; 7(6):643-54. PMID: 25998180.

View in: PubMed
Jensen JL, Rakhmilevich A, Heninger E, Broman AT, Hope C, Phan F, Miyamoto S, Maroulakou I, Callander N, Hematti P, Chesi M, Bergsagel PL, Sondel P, Asimakopoulos F. Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma. Cancer Immunol Res. 2015 Aug; 3(8):881-90. PMID: 25941352.

View in: PubMed
Callander N, Markovina S, Eickhoff J, Hutson P, Campbell T, Hematti P, Go R, Hegeman R, Longo W, Williams E, Asimakopoulos F, Miyamoto S. Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. Cancer Chemother Pharmacol. 2014 Oct; 74(4):875-82. PMID: 25168296.

View in: PubMed
Hope C, Ollar SJ, Heninger E, Hebron E, Jensen JL, Kim J, Maroulakou I, Miyamoto S, Leith C, Yang DT, Callander N, Hematti P, Chesi M, Bergsagel PL, Asimakopoulos F. TPL2 kinase regulates the inflammatory milieu of the myeloma niche. Blood. 2014 May 22; 123(21):3305-15. PMID: 24723682.

View in: PubMed
Asimakopoulos F, Kim J, Denu RA, Hope C, Jensen JL, Ollar SJ, Hebron E, Flanagan C, Callander N, Hematti P. Macrophages in multiple myeloma: emerging concepts and therapeutic implications. Leuk Lymphoma. 2013 Oct; 54(10):2112-21. PMID: 23432691.

View in: PubMed
Hebron E, Hope C, Kim J, Jensen JL, Flanagan C, Bhatia N, Maroulakou I, Mitsiades C, Miyamoto S, Callander N, Hematti P, Asimakopoulos F. MAP3K8 kinase regulates myeloma growth by cell-autonomous and non-autonomous mechanisms involving myeloma-associated monocytes/macrophages. Br J Haematol. 2013 Mar; 160(6):779-84. PMID: 23252623.

View in: PubMed
Kim J, Denu RA, Dollar BA, Escalante LE, Kuether JP, Callander NS, Asimakopoulos F, Hematti P. Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells. Br J Haematol. 2012 Aug; 158(3):336-46. PMID: 22583117.

View in: PubMed